КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ ПРОТИВОКАШЛЕВОЙ ТЕРАПИИ ПРЕПАРАТОМ РЕНГАЛИН У ПАЦИЕНТОВ С НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИЕЙ (COVID-19)

Abstract

Abstract. Introduction. Cough is one of the main symptoms of new coronavirus infection. It is known that cough development in SARS-CoV-2 infection is caused by lung epithelial cells that do not result in marked exudative inflammation, therefore, anti-cough medications should be used to treat non-productive cough in COVID-19. At the same time there is not enough data about clinical effectiveness in relieving dry cough in patients with COVID-19, and that was the reason for conducting program about symptomatic effectiveness of Rengalin in real clinical practice. Aim. The goal is to study the clinical efficacy and safety of Rengalin in comparison with standard symptomatic cough-suppressant therapy in COVID-19 patients. Material and methods. The program enrolled 100 patients, 50 of whom received the drug Rengalin and 50 patients formed the group 2, in which participants took other drugs as symptomatic cough-suppressant therapy. Cough severity was analyzed by "Cough severity scale" initially and in dynamics on the 4th, 8th day of the disease. Safety of therapy was assessed on the basis of vital signs of study participants, adverse events were recorded. Results and discussion. Use of Rengalin was accompanied by more expressed regression of cough in patients with COVID-19 in comparison with other anti-cough drugs. In the group of patients receiving Rengalin, severity of daytime cough on the 4th day of therapy made 0.6 ± 0.8 points, while in the 2nd group – 1.8 ± 1.1 points. Nocturnal cough on the 4th day of observation in the 1st group was 0.1 ± 0.3, while in the 2nd group it was 0.4 ± 0.5. In the group of patients who received Rengalin, the number of patients with absence of cough against the background of treatment was 43 (86%), while in group 2 - 27 (54%). On the 8th day of follow-up in the first group all patients noted regression of cough, in group 2 - 38 (76%). Conclusion. The results obtained expand the understanding of the physiology of cough in patients with COVID-19 and allow the successful use of Rengalin in clinical practice.